Citations 11
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Shah, Nirav N. , Ahn, Kwang Woo , Litovich, Carlos, Fenske, Timothy S. , Ahmed, Sairah , Bejanyan, Nelli , Bolaños‐Meade, Javier , Chen, Andy I. , Ciurea, Stefan O. , Bachanová, Veronika , DeFilipp, Zachariah , Epperla, Narendranath , Farhadfar, Nosha , Herrera, Alex F. , Haverkos, Bradley M. , Holmberg, Leona , Hossain, Nasheed , Kharfan‐Dabaja, Mohamed A. , Kenkre, Vaishalee P. , Murthy, Hemant S. , Rezvani, Andrew R. , D’Souza, Anita , Ulrickson, Matthew L. , Waller, Edmund K. , Sureda, Anna , Smith, Sonali M. , Holmberg, Leona , Chen, Andy , Kharfan-Dabaja, Mohamed A., D'Souza, Anita , Bachanova, Veronika , Murthy, Hemant S , Waller, Edmund K , Epperla, Narendranath , Ahmed, Sairah , Battiwalla, Minoo , Dahi, Parastoo B , Lazarus, Hillard M. , Nishihori, Taiga , Savani, Bipin N. , Hamadani, Mehdi
Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940
10.1182/bloodadvances.2018018531
Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.